Molecular Approaches for Targeting BRAF in Metastatic Colorectal Cancer
Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7% to 10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival for the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel […]
Molecular Approaches for Targeting BRAF in Metastatic Colorectal Cancer Read More »
